Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07770074 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Oct 31, 2026 → Jan 5, 2027
See other at-risk trials from Novartis

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Oct 8, 2026 to Jan 4, 2027
    • Primary and study completion pushed from Oct 31, 2026 to Jan 5, 2027
    • Secondary endpoints: details revised at 2 of 7 entries
    • Eligibility criteria expanded, about 4 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 34 trials at risk
Head & Neck Cancer
2,605 trials monitored
See 150 trials at risk
Thyroid Cancer
401 trials monitored
See 27 trials at risk
This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.
Trial Details
NCT Number NCT07770074
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Radioiodine-refractory Differentiated Thyroid Cancer
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov